Mapp expands its production efforts; Rebiotix's microbiome drug comes through in Phase II;

@FierceBiotech: EuroBiotech Report: New U.K. biotech bags £15.5M, Forbion plans €200M fund, Serono strikes oncology deal. Report | Follow @FierceBiotech

@JohnCFierce: Regado's CEO steps down as the biotech limps forward. Story | Follow @JohnCFierce

@DamianFierce: Deal: $AUXL leaves $QLTI at the altar and accepts a $2.6B offer from $ENDP. More | Follow @DamianFierce

@EmilyMFierce: At Phila. conference, how a hospital successfully treated Ebola. Story via Philly.com | Follow @EmilyMFierce

> Tiny Mapp Biopharmaceuticals is doing everything in its power to increase production of ZMapp, its unapproved treatment for the Ebola virus, working with contract manufacturers and charities including the Bill and Melinda Gates Foundation. Story

> Rebiotix's investigational Clostridium difficile treatment RBX2660 proved itself safe and effective in a Phase II trial, according to the company. More

> Synthetic Biologics ($SYN) signed a deal to raise $20.7 million in a direct offering, money it'll use to advance its pipeline of treatments for Clostridium difficile and irritable bowel syndrome. News

Medical Device News

@FierceMedDev: Researchers implant brain-controlled prosthetic arm with sensation. Story | Follow @FierceMedDev

@VarunSaxena2: Hillary Clinton hedges on the device tax, says nation must weigh pros and cons. More | Follow @VarunSaxena2

@EmilyWFierce: $MDT sans José? Release | Follow @EmilyWFierce

@MichaelGFierce: With $RHHBY's Herceptin, green tea component doubles drug accumulation in cancer cells. Article | Follow @MichaelGFierce

> C2 Therapeutics raises $11.6M for esophageal ablation. More

> Medtronic reveals corporate shakeup pending close of Covidien deal. Story

Pharma News

@FiercePharma: Tops in FierceVaccines Thurs: Takeda appoints new vaccine development head as Novartis' Oswald heads for the door. Story | Follow @FiercePharma

@CarlyHFierce: Favorite PR of the morning so far: "The holiday stress lurking beneath the gingerbread." | Follow @CarlyHFierce

> PhRMA renews legal battle over big hospital discounts for orphan drugs. News

> Bristol-Myers, Otsuka ask judge to nix Abilify kickback suit. Story

> Novartis employee pleads guilty to bribery in Poland. Article

Suggested Articles

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA Breakthrough-tagged therapy in the process.

The deal gives Sarepta exclusive licenses to four CNS targets plus an option to pay a further $42.5 million to add another four targets to the deal.

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.